One of the more spurious and naive arguments proffered by the industry's antagonists and even some people in government is that the pricing of new treatments should reflect whether public funding contributed in any way to its development. …
Latest Video
New Stories
-
NSW Premier opens Australia’s first large-scale health translation hub at UNSW
November 24, 2025 - - Latest News -
Cynata completes final patient visits in pivotal Phase 3 osteoarthritis trial
November 24, 2025 - - Australian Biotech -
New review recommends a balanced and measured approach to adopting AI in clinical practice
November 24, 2025 - - BioPharma -
Sanofi becomes first tenant of ENTRI, marking major step for Queensland’s translational research ambitions
November 24, 2025 - - Latest News -
Moderna names CSIRO scientist Dr Anne Klein as 2025 Australian Fellow
November 24, 2025 - - Australian Biotech -
‘Trojan Horse’ treatment offers hope for Australians facing relapsed multiple myeloma
November 24, 2025 - - Latest News -
New national report warns of deepening ovarian cancer burden and calls for urgent action
November 24, 2025 - - Latest News